Biographical summary
Hancheng Cai, PhD, is a radiochemist and molecular imaging scientist. My clinical work focus on FDA cGMP PET drug production facility implementation and operation. Briefly, Dr. Cai oversees all the clinical production of PET tracers at Mayo Clinic Florida, leads a team to produce FDA-approved PET drugs for daily clinical use, and investigational tracers (F-18/C-11 labeled compounds as INDs) for PET imaging of cancer
cardiovascular disease, and neurological disorders in human.
Dr. Cai's research aims to developing novel radiopharmaceuticals for the imaging and therapy of cancer, neurological disorders, and cardiovascular diseases from preclinical discovery to clinical investigation. Specifically, his research work focus on development novel radiopharmaceuticals for PET imaging of cancer biology/metabolism, immunotherapy, inflammation, and neurological disorders.
Mayo Clinic locations
Education
- 2010
Postdoctoral Research Associate - Department of RadiologyUniversity of Southern California
- 2007
PhD - Radiopharmaceuticals ScienceGraduate School of Chinese Academy of Sciences
Activities and honors
Awards and honors
- 2015
New Investigator Award in Cancer ResearchUniversity of Texas Southwestern Medical Center
- 2010
Radiopharmaceutical Sciences Council Young Investigator AwardSociety of Nuclear Medicine
- 2010
57th SNM Travel AwardSociety of Nuclear Medicine
- 2009
Travel Award18th International Symposium on Radiopharmaceutical Sciences
- 2007
USC Biomedical Imaging Science Initiative Post doctorate FellowshipUniversity of Southern California
Professional memberships
- 2014 - 2017
MemberMember, Radioactive Drug Research Committee of UTSW
- 2014 - present
MemberAmerican Chemical Society
- 2011 - present
Grant ReviewerNSF Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Program
- 2009 - present
MemberSociety of Radiopharmaceutical Sciences
- 2008 - present
MemberSociety of Nuclear Medicine and Molecular Imaging
Publications